This may be evidenced by our lack of causal association to Alzheimer’s disease and these pathways should be explored to delineate targets for therapeutic interventions that may alter neuroinflammation through S100β mediation. This evidence concerns the gene S100B and early-onset autosomal dominant Alzheimer disease.